JP2021500375A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500375A5 JP2021500375A5 JP2020523244A JP2020523244A JP2021500375A5 JP 2021500375 A5 JP2021500375 A5 JP 2021500375A5 JP 2020523244 A JP2020523244 A JP 2020523244A JP 2020523244 A JP2020523244 A JP 2020523244A JP 2021500375 A5 JP2021500375 A5 JP 2021500375A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC(C)C(C(NCC(NC(C*C(*1)=C(C(C2)C2C(NC2)=O)c3c1c(C)c(*)c(*)c3*C)C(NC(CC(*)=O)C(N(CC(C)C1)C1C([C@](C)NC(C(C)C(*)C*)C(N)=O)=O)=O)=O)=O)=O)NC2=O Chemical compound CCC(C)C(C(NCC(NC(C*C(*1)=C(C(C2)C2C(NC2)=O)c3c1c(C)c(*)c(*)c3*C)C(NC(CC(*)=O)C(N(CC(C)C1)C1C([C@](C)NC(C(C)C(*)C*)C(N)=O)=O)=O)=O)=O)=O)NC2=O 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023078719A JP7641452B2 (ja) | 2017-10-24 | 2023-05-11 | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762576572P | 2017-10-24 | 2017-10-24 | |
| US62/576,572 | 2017-10-24 | ||
| US201762596569P | 2017-12-08 | 2017-12-08 | |
| US62/596,569 | 2017-12-08 | ||
| US201862632967P | 2018-02-20 | 2018-02-20 | |
| US62/632,967 | 2018-02-20 | ||
| US201862638053P | 2018-03-02 | 2018-03-02 | |
| US62/638,053 | 2018-03-02 | ||
| PCT/US2018/057180 WO2019084064A2 (en) | 2017-10-24 | 2018-10-23 | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078719A Division JP7641452B2 (ja) | 2017-10-24 | 2023-05-11 | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500375A JP2021500375A (ja) | 2021-01-07 |
| JP2021500375A5 true JP2021500375A5 (enExample) | 2021-12-09 |
| JP7280254B2 JP7280254B2 (ja) | 2023-05-23 |
Family
ID=66247007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523244A Active JP7280254B2 (ja) | 2017-10-24 | 2018-10-23 | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
| JP2023078719A Active JP7641452B2 (ja) | 2017-10-24 | 2023-05-11 | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078719A Active JP7641452B2 (ja) | 2017-10-24 | 2023-05-11 | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10899843B2 (enExample) |
| EP (1) | EP3700568A4 (enExample) |
| JP (2) | JP7280254B2 (enExample) |
| KR (1) | KR20200069364A (enExample) |
| CN (1) | CN111372608B (enExample) |
| AU (1) | AU2018355244B2 (enExample) |
| BR (1) | BR112020008228A2 (enExample) |
| CA (1) | CA3079897A1 (enExample) |
| CO (1) | CO2020004906A2 (enExample) |
| IL (1) | IL274154A (enExample) |
| MX (1) | MX2020004140A (enExample) |
| SG (1) | SG11202003280SA (enExample) |
| WO (1) | WO2019084064A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12485186B2 (en) | 2017-03-31 | 2025-12-02 | The Children's Medical Center Corporation | Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation |
| US10882915B2 (en) | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| EP3700568A4 (en) | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| AU2018374283B2 (en) | 2017-11-29 | 2025-09-18 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD5+ cells |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| US20200376135A1 (en) * | 2018-10-23 | 2020-12-03 | Magenta Therapeutics, Inc. | Fc silenced antibody drug conjugates (adcs) and uses thereof |
| JP2022530442A (ja) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | アントラサイクリン抗体薬物複合体およびその使用 |
| EP3958878A4 (en) * | 2019-04-24 | 2022-12-28 | Magenta Therapeutics, Inc. | CONDITIONING METHODS FOR GENE THERAPY |
| WO2020219778A2 (en) * | 2019-04-24 | 2020-10-29 | Magenta Therapeutics, Inc. | Anti-cd117 antibody-drug conjugates and uses thereof |
| CA3134319A1 (en) * | 2019-04-24 | 2020-10-29 | Rahul Palchaudhuri | Anti-cd117 antibodies and uses thereof |
| WO2020216947A1 (en) * | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| AU2020289360A1 (en) | 2019-06-04 | 2022-01-20 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for treating autoimmune diseases |
| CN114206358A (zh) * | 2019-06-05 | 2022-03-18 | 美真达治疗公司 | T细胞消耗疗法 |
| EP4121462A4 (en) * | 2020-03-16 | 2024-04-24 | Magenta Therapeutics, Inc. | BISPECIFIC T CELL BINDING PROTEINS |
| WO2023002415A2 (en) * | 2021-07-20 | 2023-01-26 | Magenta Therapeutics, Inc. | Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment |
| IL313568A (en) | 2021-12-16 | 2024-08-01 | Universit?T Basel | Distinct cell membrane protein variants of CD117 for use in cellular therapy |
| EP4551601A1 (en) | 2022-07-07 | 2025-05-14 | Cimeio Therapeutics AG | Antibodies targeting cd117 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19600589C1 (de) * | 1996-01-10 | 1997-01-16 | Univ Eberhard Karls | Antikörper A3C6E2 |
| US6093795A (en) | 1996-12-13 | 2000-07-25 | Human Genome Sciences, Inc. | Isolated human Prt1 protein |
| US6372448B1 (en) | 1998-12-30 | 2002-04-16 | Millennium Pharmaceuticals, Inc. | Use of ylqF, yqeG, yybQ, and ysxC, essential bacterial genes and polypeptides |
| US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| US8716195B2 (en) | 2005-11-14 | 2014-05-06 | Bioren, Inc. | Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening |
| TWI395754B (zh) * | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| ATE521366T1 (de) | 2006-05-27 | 2011-09-15 | Faulstich Heinz Dr | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen |
| EP3255061B1 (en) * | 2006-11-03 | 2021-06-16 | The Board of Trustees of the Leland Stanford Junior University | Selective immunodepletion of endogenous stem cell niche for engraftment |
| US8119130B2 (en) | 2007-07-25 | 2012-02-21 | Medimmune Limited | Targeted binding agents directed to KDR and uses thereof—035 |
| DK3290052T3 (da) | 2008-11-07 | 2020-02-03 | Galaxy Biotech Llc | Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2 |
| JO3096B1 (ar) | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| EP3192529B1 (en) | 2009-04-08 | 2020-03-25 | Faulstich, Heinz, Dr. | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
| JP2013521758A (ja) | 2010-02-18 | 2013-06-13 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 緑膿菌の血清型ａ型リポ多糖に対する抗体 |
| BR112013002444A2 (pt) | 2010-08-13 | 2016-05-24 | Roche Glycart Ag | anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo |
| ES2402254T3 (es) | 2010-09-30 | 2013-04-30 | Heidelberg Pharma Ag | Conjugados de amatoxinas con ligadores mejorados |
| US20120189612A1 (en) * | 2011-01-25 | 2012-07-26 | The Cleveland Clinic Foundation | Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy |
| US20120189633A1 (en) * | 2011-01-26 | 2012-07-26 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
| AR086044A1 (es) * | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
| FR3008408B1 (fr) | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
| WO2015006475A1 (en) | 2013-07-12 | 2015-01-15 | Biogen Idec International Neuroscience Gmbh | Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease |
| WO2015057942A1 (en) | 2013-10-18 | 2015-04-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides |
| US9932410B2 (en) * | 2013-11-05 | 2018-04-03 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Human neutralizing anti-kit antibodies and uses thereof |
| WO2015138600A2 (en) | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| WO2016020791A1 (en) * | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| EP3215519A1 (en) | 2014-11-06 | 2017-09-13 | Novartis AG | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
| DK3268047T3 (da) * | 2015-03-09 | 2024-01-02 | Heidelberg Pharma Res Gmbh | Amatoxin/antistof-konjugater |
| EP3273984B1 (en) | 2015-03-25 | 2021-05-05 | Children's Hospital Medical Center | Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation |
| HK1256681A1 (zh) | 2015-04-06 | 2019-10-04 | President And Fellows Of Harvard College | 用於非清髓性预处理的组合物和方法 |
| EP3991748A3 (en) | 2015-04-07 | 2022-08-24 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| US10683506B2 (en) | 2015-04-10 | 2020-06-16 | The Methodist Hospital System | CD117 ligand-drug conjugates for targeted cancer therapy |
| MY206406A (en) | 2015-10-02 | 2024-12-16 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| KR20180104148A (ko) | 2016-02-05 | 2018-09-19 | 젠맵 에이/에스 | 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자 |
| MX2018012803A (es) | 2016-04-20 | 2019-06-24 | Hangzhou Dac Biotech Co Ltd | Derivados de las toxinas de amanita y su conjugacion a una molecula de union celular. |
| US10464969B2 (en) | 2016-05-05 | 2019-11-05 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
| US10111966B2 (en) | 2016-06-17 | 2018-10-30 | Magenta Therapeutics, Inc. | Methods for the depletion of CD117+ cells |
| US12485186B2 (en) | 2017-03-31 | 2025-12-02 | The Children's Medical Center Corporation | Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation |
| US10882915B2 (en) | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| EP3700568A4 (en) | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
-
2018
- 2018-10-23 EP EP18870545.3A patent/EP3700568A4/en active Pending
- 2018-10-23 JP JP2020523244A patent/JP7280254B2/ja active Active
- 2018-10-23 AU AU2018355244A patent/AU2018355244B2/en not_active Expired - Fee Related
- 2018-10-23 WO PCT/US2018/057180 patent/WO2019084064A2/en not_active Ceased
- 2018-10-23 KR KR1020207014624A patent/KR20200069364A/ko active Pending
- 2018-10-23 CN CN201880075607.2A patent/CN111372608B/zh active Active
- 2018-10-23 CA CA3079897A patent/CA3079897A1/en active Pending
- 2018-10-23 MX MX2020004140A patent/MX2020004140A/es unknown
- 2018-10-23 SG SG11202003280SA patent/SG11202003280SA/en unknown
- 2018-10-23 US US16/168,823 patent/US10899843B2/en active Active
- 2018-10-23 BR BR112020008228-7A patent/BR112020008228A2/pt not_active Application Discontinuation
-
2020
- 2020-04-21 CO CONC2020/0004906A patent/CO2020004906A2/es unknown
- 2020-04-22 IL IL274154A patent/IL274154A/en unknown
- 2020-11-24 US US17/103,866 patent/US11958908B2/en active Active
-
2023
- 2023-05-11 JP JP2023078719A patent/JP7641452B2/ja active Active
-
2024
- 2024-04-04 US US18/626,765 patent/US20240360238A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7641452B2 (ja) | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 | |
| US11572411B2 (en) | Anti-CD117 antibodies and conjugates | |
| JP7791923B2 (ja) | Ｃｄ５＋細胞の枯渇のための組成物および方法 | |
| JP7669269B2 (ja) | 抗－ｃｄ４５抗体及びそのコンジュゲート | |
| JP7709376B2 (ja) | Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用 | |
| JP7716399B2 (ja) | 抗－ｃｄ４５抗体及びそのコンジュゲート | |
| JP2025038016A (ja) | 同種異系の造血幹細胞移植の方法 | |
| US20220177575A1 (en) | Anti-cd117 antibodies and uses thereof | |
| JP2022529726A5 (enExample) | ||
| JP2021504414A (ja) | Ｃｄ２＋細胞の枯渇のための組成物および方法 | |
| US20220177578A1 (en) | Anti-cd117 antibodies and uses thereof | |
| JP2022529727A5 (enExample) | ||
| EP3740233A2 (en) | Compositions and methods for the depletion of cd134+ cells |